Black Diamond Therapeutics Inc (BDTX)

[dcaf7]

Silevertinib ASCO presentation noticed.
The second confirmed presentation focuses on a high-need molecular space: frontline non-classical EGFR NSCLC with silevertinib (BDTX-1535). The prior dataset cited in the cards reported ORR 60%, CNS ORR 86%, and disease control rate 91%, while targeting more than 50 non-classical EGFR mutations, including exon 20 insertions. The update will likely be watched closely because this is exactly the kind of setting where durability matters as much as early activity. If duration of response and progression-free survival remain strong, silevertinib could become one of the most important emerging drugs in a space still lacking a clean frontline standard.
https://oncodaily.com/oncolibrary/lung-oncology/asco-2026-lung